References
- Rajpal R, Dowling P, Meiller J et al. A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics11(8), 1391–1402 (2011).
- Cavallo F, Boccadoro M, Palumbo A. Review of thalidomide in the treatment of newly diagnosed multiple myeloma. Ther. Clin. Risk Manag.3(4), 543–552 (2007).
- Gao Y, Holland RD, Yu LR. Quantitative proteomics for drug toxicity. Brief Funct. Genomic Proteomic8(2), 158–166 (2009).
- Chakravarti B, Mallik B, Chakravarti DN. Proteomics and systems biology: application in drug discovery and development. Methods Mol. Biol.662, 3–28 (2010).
- Rabilloud T, Chevallet M, Luche S, Lelong C. Two-dimensional gel electrophoresis in proteomics: past, present and future. J. Proteomics73(11), 2064–2077 (2010).
- Elliott MH, Smith DS, Parker CE, Borchers C. Current trends in quantitative proteomics. J. Mass Spectrom.44(12), 1637–1660 (2009).
- De Bock M, de Seny D, Meuwis MA et al. Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. J. Biomed. Biotechnol.2010, 906082 (2010).
- Yang L, Guo S, Li Y, Zhou S, Tao S. Protein microarrays for systems biology. Acta Biochim. Biophys. Sin. (Shanghai)43(3), 161–171 (2011).
- Tedford NC, Hall AB, Graham JR, Murphy CE, Gordon NF, Radding JA. Quantitative analysis of cell signaling and drug action via mass spectrometry-based systems level phosphoproteomics. Proteomics9(6), 1469–1487 (2009).
- Tian Y, Zhang H. Glycoproteomics and clinical applications. Proteomics Clin. Appl.4(2), 124–132 (2010).